{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:03Z","timestamp":1793155743679,"version":"4.5.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["302384\/2022-7"],"award-info":[{"award-number":["302384\/2022-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2023\/17075-5"],"award-info":[{"award-number":["2023\/17075-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2024\/10691-5"],"award-info":[{"award-number":["2024\/10691-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2019\/05843-2"],"award-info":[{"award-number":["2019\/05843-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["202310HIV-515690-410883"],"award-info":[{"award-number":["202310HIV-515690-410883"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-166153"],"award-info":[{"award-number":["PJT-166153"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2021-03072"],"award-info":[{"award-number":["RGPIN-2021-03072"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119691","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:51:17Z","timestamp":1782471077000},"page":"119691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Next-generation drug delivery systems for aspergillosis: Overcoming barriers in antifungal therapy"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-7004","authenticated-orcid":false,"given":"Yugo A.","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma T.","family":"Anselmo-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Tamashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel A.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-5317","authenticated-orcid":false,"given":"Fabiana C.P.","family":"Valera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119691_bib1","doi-asserted-by":"crossref","first-page":"069","DOI":"10.1055\/s-0043-1777769","article-title":"Acute invasive pulmonary aspergillosis: clinical presentation and treatment","volume":"45","author":"Heylen","year":"2024","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119691_bib2","article-title":"Aspergillus fumigatus \u2014a systematic review to inform the World Health Organization priority list of fungal pathogens","volume":"62","author":"Morrissey","year":"2024","journal-title":"Med. Mycol."},{"key":"10.1016\/j.biopha.2026.119691_bib3","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/IAI.01353-09","article-title":"Secreted aspergillus fumigatus protease Alp1 degrades human complement proteins C3, C4, and C5","volume":"78","author":"Behnsen","year":"2010","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2026.119691_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003575","article-title":"Aspergillus galactosaminogalactan mediates adherence to host constituents and conceals hyphal \u03b2-glucan from the immune system","volume":"9","author":"Gravelat","year":"2013","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.biopha.2026.119691_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2016.00472","article-title":"Interactions of aspergillus fumigatus conidia with airway epithelial cells: a critical review","volume":"7","author":"Croft","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2026.119691_bib6","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1128\/IAI.01726-14","article-title":"Surface structure characterization of aspergillus fumigatus conidia mutated in the melanin synthesis pathway and their human cellular immune response","volume":"82","author":"Bayry","year":"2014","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2026.119691_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978152","article-title":"Protective role of host complement system in Aspergillus fumigatus infection","volume":"13","author":"Shende","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib8","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.4049\/jimmunol.177.6.3994","article-title":"Aspergillus fumigatus Induces Innate Immune Responses in Alveolar Macrophages through the MAPK Pathway Independently of TLR2 and TLR4","volume":"177","author":"Dubourdeau","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib9","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.4049\/jimmunol.0804250","article-title":"Requisite Role for the Dectin-1 \u03b2-Glucan Receptor in Pulmonary Defense against Aspergillus fumigatus","volume":"182","author":"Werner","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib10","doi-asserted-by":"crossref","first-page":"003","DOI":"10.1055\/s-0043-1777259","article-title":"Aspergillus and the Lung","volume":"45","author":"Janssens","year":"2024","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119691_bib11","unstructured":"World Health Organization, WHO fungal priority pathogens list to guide research, development and public health action, (2022) \u3008https:\/\/iris.who.int\/bitstream\/handle\/10665\/363682\u3009. \u3008https:\/\/iris.who.int\/bitstream\/handle\/10665\/363682\/9789240060241-eng.pdf?sequence=1\u3009."},{"key":"10.1016\/j.biopha.2026.119691_bib12","article-title":"Global incidence and mortality of severe fungal disease","author":"Denning","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/jof10110733","article-title":"Healthcare Costs of Hospitalizations Due to Aspergillosis and 25-Year Trends in Spain, 1997\u20132021","volume":"10","author":"Rinc\u00f3n Villar","year":"2024","journal-title":"J. Fungi"},{"key":"10.1016\/j.biopha.2026.119691_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/ciad546","article-title":"High Burden of COVID-19-Associated Pulmonary Aspergillosis in Severely Immunocompromised Patients Requiring Mechanical Ventilation","volume":"78","author":"Feys","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib15","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of Direct Healthcare Costs of Fungal Diseases in the United States","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib16","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/jof7080599","article-title":"Azole-Resistance Development; How the Aspergillus fumigatus Lifecycle Defines the Potential for Adaptation","volume":"7","author":"Zhang","year":"2021","journal-title":"J. Fungi"},{"key":"10.1016\/j.biopha.2026.119691_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3109\/08880018.2015.1092058","article-title":"Acute Invasive Fungal Rhinosinusitis in Children With Hematologic Malignancies: Outcome of Surgical Treatment","volume":"32","author":"Yakirevitch","year":"2015","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119691_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MOO.0000000000000507","article-title":"Updates in management of acute invasive fungal rhinosinusitis","volume":"27","author":"Craig","year":"2019","journal-title":"Curr. Opin. Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.biopha.2026.119691_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jcms.2015.12.016","article-title":"Invasive fungal rhinosinusitis in adult patients: Our experience in diagnosis and management","volume":"44","author":"Pagella","year":"2016","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"10.1016\/j.biopha.2026.119691_bib21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.biopha.2026.119691_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2026.119691_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1513\/pats.200908-086AL","article-title":"Allergic Bronchopulmonary Aspergillosis","volume":"7","author":"Patterson","year":"2010","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.biopha.2026.119691_bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance","volume":"6","author":"Ellsworth","year":"2020","journal-title":"J. Fungi"},{"key":"10.1016\/j.biopha.2026.119691_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/jof7020076","article-title":"Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients","volume":"7","author":"Klatt","year":"2021","journal-title":"J. Fungi"},{"key":"10.1016\/j.biopha.2026.119691_bib27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/ctr.12834","article-title":"Adverse effects of voriconazole: Over a decade of use","volume":"30","author":"Levine","year":"2016","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.biopha.2026.119691_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121430","article-title":"Advances in controlled drug delivery to the sinonasal mucosa","volume":"282","author":"Schilling","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119691_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejpb.2019.09.002","article-title":"Challenges and strategies in drug delivery systems for treatment of pulmonary infections","volume":"144","author":"Ho","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119691_bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","article-title":"Nasal drug delivery devices: characteristics and performance in a clinical perspective\u2014a review","volume":"3","author":"Djupesland","year":"2013","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119691_bib31","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1166\/jnn.2015.10341","article-title":"Breathable Medicine: Pulmonary Mode of Drug Delivery","volume":"15","author":"Gandhimathi","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.biopha.2026.119691_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","article-title":"Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art","volume":"86","author":"Weber","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119691_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00049-19","article-title":"Molecular Mechanisms of Conidial Germination in Aspergillus spp","volume":"84","author":"Baltussen","year":"2020","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.biopha.2026.119691_bib34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0732-8893(99)00026-7","article-title":"Epidemiology of nosocomial fungal infections: invasive aspergillosis and the environment","volume":"34","author":"VandenBergh","year":"1999","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1128\/CMR.00014-09","article-title":"Innate Immunity to Aspergillus Species","volume":"22","author":"Park","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.biopha.2026.119691_bib36","article-title":"N. W\u00e9ry, Bioaerosols from composting facilities\u2014a review","volume":"4","year":"2014","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2026.119691_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00140-18","article-title":"Aspergillus fumigatus and Aspergillosis in 2019","volume":"33","author":"Latg\u00e9","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.biopha.2026.119691_bib38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/CMR.00055-08","article-title":"Pathogenesis of Aspergillus fumigatus in invasive aspergillosis","volume":"22","author":"Dagenais","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.biopha.2026.119691_bib39","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1128\/IAI.68.6.3377-3384.2000","article-title":"Adhesion of Aspergillus Species to Extracellular Matrix Proteins: Evidence for Involvement of Negatively Charged Carbohydrates on the Conidial Surface","volume":"68","author":"Wasylnka","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2026.119691_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009794","article-title":"Aspergillus fumigatus biofilms: Toward understanding how growth as a multicellular network increases antifungal resistance and disease progression","volume":"17","author":"Morelli","year":"2021","journal-title":"PLOS Pathog."},{"key":"10.1016\/j.biopha.2026.119691_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002372","article-title":"Galactosaminogalactan, a New Immunosuppressive Polysaccharide of Aspergillus fumigatus","volume":"7","author":"Fontaine","year":"2011","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.biopha.2026.119691_bib42","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1080\/21505594.2019.1568174","article-title":"Galactosaminogalactan (GAG) and its multiple roles in Aspergillus pathogenesis","volume":"10","author":"Speth","year":"2019","journal-title":"Virulence"},{"key":"10.1016\/j.biopha.2026.119691_bib43","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1128\/iai.65.8.3171-3179.1997","article-title":"Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages","volume":"65","author":"Madan","year":"1997","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2026.119691_bib44","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1128\/IAI.69.4.2728-2731.2001","article-title":"Protective Role of Lung Surfactant Protein D in a Murine Model of Invasive Pulmonary Aspergillosis","volume":"69","author":"Madan","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2026.119691_bib45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1172\/JCI10124","article-title":"Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens","volume":"107","author":"Madan","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2026.119691_bib46","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1128\/iai.57.11.3412-3417.1989","article-title":"Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae","volume":"57","author":"Kozel","year":"1989","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2026.119691_bib47","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1128\/iai.60.5.1913-1918.1992","article-title":"Interactions between conidia of Aspergillus fumigatus and human complement component C3","volume":"60","author":"Sturtevant","year":"1992","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2026.119691_bib48","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/IAI.68.2.688-693.2000","article-title":"Mannose-Binding Lectin Binds to a Range of Clinically Relevant Microorganisms and Promotes Complement Deposition","volume":"68","author":"Neth","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2026.119691_bib49","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2249.2007.03351.x","article-title":"Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis","volume":"148","author":"Kaur","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib50","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.4049\/jimmunol.181.10.7100","article-title":"Aspergillus Conidia Activate the Complement by the Mannan-Binding Lectin C2 Bypass Mechanism","volume":"181","author":"Dumestre-P\u00e9rard","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib51","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature01195","article-title":"Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response","volume":"420","author":"Garlanda","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119691_bib52","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1084\/jem.20061301","article-title":"The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps","volume":"204","author":"Jaillon","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2026.119691_bib53","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1128\/IAI.73.9.5420-5425.2005","article-title":"Involvement of Toll-Like Receptor 2 in Experimental Invasive Pulmonary Aspergillosis","volume":"73","author":"Balloy","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2026.119691_bib54","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.4049\/jimmunol.172.5.3059","article-title":"The Contribution of the Toll-Like\/IL-1 Receptor Superfamily to Innate and Adaptive Immunity to Fungal Pathogens In Vivo","volume":"172","author":"Bellocchio","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib55","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.4049\/jimmunol.173.12.7406","article-title":"TLRs Govern Neutrophil Activity in Aspergillosis","volume":"173","author":"Bellocchio","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib56","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.4049\/jimmunol.176.6.3717","article-title":"Dectin-1 and TLRs Permit Macrophages to Distinguish between Different Aspergillus fumigatus Cellular States","volume":"176","author":"Gersuk","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib57","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1462-5822.2006.00796.x","article-title":"Phagocytosis of Aspergillus fumigatus conidia by murine macrophages involves recognition by the dectin-1 beta-glucan receptor and Toll-like receptor 2","volume":"9","author":"Luther","year":"2007","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.biopha.2026.119691_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0010042","article-title":"The Beta-Glucan Receptor Dectin-1 Recognizes Specific Morphologies of Aspergillus fumigatus","volume":"1","author":"Steele","year":"2005","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.biopha.2026.119691_bib59","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.4049\/jimmunol.173.9.5635","article-title":"Dendritic Cell-Specific Intercellular Adhesion Molecule 3-Grabbing Nonintegrin Mediates Binding and Internalization of Aspergillus fumigatus Conidia by Dendritic Cells and Macrophages","volume":"173","author":"Serrano-G\u00f3mez","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nri1255","article-title":"Immunity to fungal infections","volume":"4","author":"Romani","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111290","article-title":"Different forms of pulmonary aspergillosis: A pictorial essay","volume":"171","author":"Tamkeviciute","year":"2024","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.biopha.2026.119691_bib62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.anai.2023.02.018","article-title":"Update on allergic fungal rhinosinusitis","volume":"131","author":"Chua","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.biopha.2026.119691_bib63","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12105-016-0690-0","article-title":"Pathology of Fungal Rhinosinusitis: A Review","volume":"10","author":"Montone","year":"2016","journal-title":"Head. Neck Pathol."},{"key":"10.1016\/j.biopha.2026.119691_bib64","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/lary.20520","article-title":"Fungal rhinosinusitis","volume":"119","author":"Chakrabarti","year":"2009","journal-title":"Laryngoscope"},{"key":"10.1016\/j.biopha.2026.119691_bib65","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1288\/00005537-196505000-00004","article-title":"Primary aspergillosis of the paranasal sinuses and associated areas","volume":"75","author":"Hora","year":"1965","journal-title":"Laryngoscope"},{"key":"10.1016\/j.biopha.2026.119691_bib66","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/j.ijid.2011.08.005","article-title":"Prognosis of acute invasive fungal rhinosinusitis related to underlying disease","volume":"15","author":"Valera","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib67","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12879-019-3938-y","article-title":"Impact of early detection of acute invasive fungal rhinosinusitis in immunocompromised patients","volume":"19","author":"Silveira","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib68","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","article-title":"Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients","volume":"67","author":"Maschmeyer","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2026.119691_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106720","article-title":"Mortality outcomes associated with invasive aspergillosis among acute exacerbation of chronic obstructive pulmonary disease patient population","volume":"191","author":"Mir","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.biopha.2026.119691_bib70","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1469-0691.2009.03015.x","article-title":"Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome","volume":"16","author":"Guinea","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.biopha.2026.119691_bib71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12890-020-01259-8","article-title":"The global impact of Aspergillus infection on COPD","volume":"20","author":"Hammond","year":"2020","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.biopha.2026.119691_bib72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/myc.13403","article-title":"Invasive fungal infections in acute and chronic liver impairment: A systematic review","volume":"65","author":"Lahmer","year":"2022","journal-title":"Mycoses"},{"key":"10.1016\/j.biopha.2026.119691_bib73","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/liv.13981","article-title":"Invasive fungal infections amongst patients with acute-on-chronic liver failure at high risk for fungal infections","volume":"39","author":"Verma","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2026.119691_bib74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhep.2013.09.011","article-title":"Invasive aspergillosis in patients with severe alcoholic hepatitis","volume":"60","author":"Gustot","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119691_bib75","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-019-0502-2","article-title":"Invasive pulmonary aspergillosis in cirrhotic patients: analysis of a 10-year clinical experience","volume":"9","author":"Levesque","year":"2019","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.biopha.2026.119691_bib76","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1164\/rccm.201612-2540LE","article-title":"Influenza-associated Aspergillosis in Critically Ill Patients","volume":"196","author":"van de Veerdonk","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119691_bib77","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/myc.13410","article-title":"Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: A systematic review and meta-analysis","volume":"65","author":"Shi","year":"2022","journal-title":"Mycoses"},{"key":"10.1016\/j.biopha.2026.119691_bib78","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/CCM.0000000000004861","article-title":"The Extent of Aspergillosis in Critically Ill Patients With Severe Influenza Pneumonia: A Multicenter Cohort Study","volume":"49","author":"Coste","year":"2021","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119691_bib79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00134-016-4578-y","article-title":"Increased incidence of co-infection in critically ill patients with influenza","volume":"43","author":"Martin-Loeches","year":"2017","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.biopha.2026.119691_bib80","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00134-021-06510-2","article-title":"COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges","volume":"47","author":"Prattes","year":"2021","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.biopha.2026.119691_bib81","doi-asserted-by":"crossref","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study","volume":"73","author":"Bartoletti","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib82","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1080\/13693780802314809","article-title":"Allergic fungal sinusitis: pathophysiology, diagnosis and management","volume":"47","author":"Schubert","year":"2009","journal-title":"Med. Mycol."},{"key":"10.1016\/j.biopha.2026.119691_bib83","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11046-015-9885-2","article-title":"Activity and Safety of Inhaled Itraconazole Nanosuspension in a Model Pulmonary Aspergillus fumigatus Infection in Inoculated Young Quails","volume":"180","author":"Wla\u017a","year":"2015","journal-title":"Mycopathologia"},{"key":"10.1016\/j.biopha.2026.119691_bib84","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejpb.2012.09.018","article-title":"Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis","volume":"83","author":"Rundfeldt","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119691_bib85","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejpb.2016.07.018","article-title":"Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons","volume":"108","author":"Pardeike","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119691_bib86","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.2147\/IJN.S34091","article-title":"New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis","volume":"7","author":"Duret","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119691_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.114134","article-title":"Dandelion inspired microparticles with highly efficient drug delivery to deep lung","volume":"244","author":"Sun","year":"2024","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2026.119691_bib88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/jof2020017","article-title":"Allergic Bronchopulmonary Aspergillosis","volume":"2","author":"Tracy","year":"2016","journal-title":"J. Fungi"},{"key":"10.1016\/j.biopha.2026.119691_bib89","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/alr.22093","article-title":"Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery","volume":"8","author":"Harvey","year":"2018","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.biopha.2026.119691_bib90","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/cea.12333","article-title":"Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: a systematic review","volume":"44","author":"Moreira","year":"2014","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.biopha.2026.119691_bib91","unstructured":"Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome (GLITZ), ClinicalTrials.Gov. (2025). \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT05444946?cond=%22Aspergillosis%22&viewType=Table&page=4&rank=35\u3009."},{"key":"10.1016\/j.biopha.2026.119691_bib92","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pccm.2024.11.005","article-title":"Treatment of allergic bronchopulmonary aspergillosis with biologics","volume":"3","author":"Asano","year":"2025","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119691_bib93","article-title":"Anti\u2013IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis","volume":"4","author":"Lamothe","year":"2025","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"10.1016\/j.biopha.2026.119691_bib94","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119691_bib95","unstructured":"Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (INCAS), ClinicalTrials.Gov. (2025). \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT05653193?cond=%22Aspergillosis%22&viewType=Table&rank=3\u3009."},{"key":"10.1016\/j.biopha.2026.119691_bib96","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib97","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B Lipid Complex for Invasive Fungal Infections: Analysis of Safety and Efficacy in 556 Cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib98","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.10126","article-title":"Characterization of the interaction of 2-hydroxypropyl-\u03b2-cyclodextrin with itraconazole at pH 2, 4, and 7","volume":"91","author":"Peeters","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119691_bib99","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/jac\/dkg434","article-title":"C.C. Kibbler, Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B","volume":"52","author":"Paterson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2026.119691_bib100","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019737","article-title":"Treatment Principles for the Management of Mold Infections","volume":"5","author":"Kontoyiannis","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2026.119691_bib101","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10096-005-0080-0","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis","volume":"25","author":"Girois","year":"2006","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.biopha.2026.119691_bib102","unstructured":"Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study), ClinicalTrials.Gov. (2025). \u3008https:\/\/clinicaltrials.gov\/study\/NCT05238116#study-record-dates\u3009."},{"key":"10.1016\/j.biopha.2026.119691_bib103","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.drudis.2014.09.020","article-title":"Recent advances in controlled pulmonary drug delivery","volume":"20","author":"Liang","year":"2015","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.biopha.2026.119691_bib104","series-title":"in: Nasal Drug Deliv","first-page":"339","article-title":"Nasal Delivery of Micro and Nano Encapsulated Drugs","author":"Sarfraz","year":"2023"},{"key":"10.1016\/j.biopha.2026.119691_bib105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1208\/s12249-020-01837-3","article-title":"Bigger or Smaller? Size and Loading Effects on Nanoparticle Uptake Efficiency in the Nasal Mucosa","volume":"21","author":"Albarki","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.biopha.2026.119691_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2021.102432","article-title":"Mucoadhesive and mucus-penetrating interpolyelectrolyte complexes for nose-to-brain drug delivery","volume":"37","author":"Porfiryeva","year":"2021","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2026.119691_bib107","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/17425247.4.6.595","article-title":"The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects","volume":"4","author":"Rogueda","year":"2007","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.biopha.2026.119691_bib108","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.3390\/ijms21145016","article-title":"New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan","volume":"21","author":"Popescu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119691_bib109","article-title":"PLGA nanoparticles for nasal drug delivery","volume":"95","author":"Alghareeb","year":"2024","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119691_bib110","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s13346-023-01450-4","article-title":"Construction of PLGA nanoparticles modified with RWrNM and DLPC and their application in acute rhinosinusitis","volume":"14","author":"Tao","year":"2024","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119691_bib111","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1021\/acsomega.0c00111","article-title":"Developing Biodegradable Nanoparticles Loaded with Mometasone Furoate for Potential Nasal Drug Delivery","volume":"5","author":"Far","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2026.119691_bib112","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejps.2019.02.015","article-title":"Cromolyn-crosslinked chitosan nanoparticles for the treatment of allergic rhinitis","volume":"131","author":"Abruzzo","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119691_bib113","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.ijbiomac.2019.05.188","article-title":"Nasal adaptive chitosan-based nano-vehicles for anti-allergic drug delivery","volume":"135","author":"Sun","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2026.119691_bib114","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1016\/j.biomaterials.2011.05.008","article-title":"Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus","volume":"32","author":"Lai","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119691_bib115","article-title":"Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119691_bib116","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2147\/IJN.S98547","article-title":"Rationally designed nanocarriers for intranasal therapy of allergic rhinitis: influence of carrier type on in vivo nasal deposition","author":"Sallam","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119691_bib117","article-title":"Astragalus Polysaccharides\/Chitosan Microspheres for Nasal Delivery: Preparation, Optimization, Characterization, and Pharmacodynamics","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119691_bib118","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/03639045.2013.782503","article-title":"Budesonide\/cyclodextrin complex-loaded lyophilized microparticles for intranasal application","volume":"40","author":"Kim","year":"2014","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib119","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ijbiomac.2020.07.138","article-title":"Fabrication of chitosan\/polyvinylpyrrolidone hydrogel scaffolds containing PLGA microparticles loaded with dexamethasone for biomedical applications","volume":"164","author":"Saeedi Garakani","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2026.119691_bib120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/pharmaceutics12100907","article-title":"Chitosan Hydrogel Doped with PEG-PLA Nanoparticles for the Local Delivery of miRNA-146a to Treat Allergic Rhinitis","volume":"12","author":"Su","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119691_bib121","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jconrel.2020.10.062","article-title":"A thermoresponsive hydrogel system for long-acting corticosteroid delivery into the paranasal sinuses","volume":"330","author":"Schilling","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119691_bib122","article-title":"Injectable and Self-Healing Hydrogel with Anti-Bacterial and Anti-Inflammatory Properties for Acute Bacterial Rhinosinusitis with Micro Invasive Treatment","volume":"9","author":"Chen","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.biopha.2026.119691_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106694","article-title":"The challenges and opportunities of \u03b1v\u03b23-based therapeutics in cancer: From bench to clinical trials","volume":"189","author":"Gu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2026.119691_bib124","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/pharmaceutics15010105","article-title":"Pharmacokinetic Study of Intranasal Dexamethasone and Methylprednisolone Compared with Intravenous Administration: Two Open-Label, Single-Dose, Two-Period, Two-Sequence, Cross-Over Study in Healthy Volunteers","volume":"15","author":"C\u00e1rdenas","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119691_bib125","first-page":"56","article-title":"Review of Astragalus membranaceus polysaccharides: Extraction process, structural features, bioactivities and applications","volume":"17","author":"Tian","year":"2025","journal-title":"Chin. Herb. Med."},{"key":"10.1016\/j.biopha.2026.119691_bib126","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2273.1999.00223.x","article-title":"Nasal pH measurement: a reliable and repeatable parameter","volume":"24","author":"England","year":"1999","journal-title":"Clin. Otolaryngol. Allied Sci."},{"key":"10.1016\/j.biopha.2026.119691_bib127","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.amjoto.2013.04.015","article-title":"Nasal pH in patients with chronic rhinosinusitis before and after endoscopic sinus surgery","volume":"34","author":"Kim","year":"2013","journal-title":"Am. J. Otolaryngol."},{"key":"10.1016\/j.biopha.2026.119691_bib128","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1021\/acs.molpharmaceut.1c00366","article-title":"Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs","volume":"18","author":"Clementino","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib129","doi-asserted-by":"crossref","DOI":"10.4209\/aaqr.210098","article-title":"Optimising Aerosol Delivery for Maxillary Sinus Deposition in a Post-FESS Sinonasal Cavities","volume":"21","author":"Vahaji","year":"2021","journal-title":"Aerosol Air Qual. Res."},{"key":"10.1016\/j.biopha.2026.119691_bib130","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/lary.30155","article-title":"Intranasal Spray Characteristics for Best Drug Delivery in Patients With Chronic Rhinosinusitis","volume":"133","author":"Popper","year":"2023","journal-title":"Laryngoscope"},{"key":"10.1016\/j.biopha.2026.119691_bib131","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.3390\/ijms24065441","article-title":"Microparticles in the Development and Improvement of Pharmaceutical Formulations: An Analysis of In Vitro and In Vivo Studies","volume":"24","author":"da Silva","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119691_bib132","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(13)70072-9","article-title":"Pulmonary drug delivery: from generating aerosols to overcoming biological barriers\u2014therapeutic possibilities and technological challenges","volume":"1","author":"Ruge","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2026.119691_bib133","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jconrel.2024.06.044","article-title":"Enhancing pulmonary delivery and immunomodulation of respiratory diseases through virus-mimicking nanoparticles","volume":"372","author":"Martins","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119691_bib134","article-title":"Novel Wide-Spectrum Virucidal Lipid Nanoparticles","volume":"22","author":"Martins","year":"2026","journal-title":"Small"},{"key":"10.1016\/j.biopha.2026.119691_bib135","article-title":"Nanotherapeutics for pulmonary drug delivery: An emerging approach to overcome respiratory diseases","volume":"81","author":"Kole","year":"2023","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119691_bib136","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s13346-018-0550-4","article-title":"Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations","volume":"8","author":"Ngan","year":"2018","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119691_bib137","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijpharm.2008.01.008","article-title":"Solid lipid nanoparticles for pulmonary delivery of insulin","volume":"356","author":"Liu","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib138","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2147\/IJN.S57565","article-title":"Formulation and delivery of itraconazole to the brain using a nanolipid carrier system","author":"Lim","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119691_bib139","doi-asserted-by":"crossref","first-page":"57","DOI":"10.15171\/apb.2016.009","article-title":"Aggregated Nanotransfersomal Dry Powder Inhalation of Itraconazole for Pulmonary Drug Delivery","volume":"6","author":"Hassanpour Aghdam","year":"2016","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.biopha.2026.119691_bib140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.powtec.2012.01.045","article-title":"Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation","volume":"222","author":"Jafarinejad","year":"2012","journal-title":"Powder Technol."},{"key":"10.1016\/j.biopha.2026.119691_bib141","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2017.09.024","article-title":"Development of fine solid-crystal suspension with enhanced solubility, stability, and aerosolization performance for dry powder inhalation","volume":"533","author":"Lin","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib142","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jddst.2016.12.009","article-title":"Optimization and scaling-up of ITZ-based dry powders for inhalation","volume":"37","author":"Merlos","year":"2017","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119691_bib143","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejpb.2010.01.011","article-title":"Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats","volume":"75","author":"Yang","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119691_bib144","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s11095-012-0779-4","article-title":"New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis","volume":"29","author":"Duret","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2026.119691_bib145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejpb.2013.03.005","article-title":"Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention","volume":"86","author":"Duret","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119691_bib146","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2217\/nnm-2017-0291","article-title":"Chitosan-coated Nanoparticles Enhanced Lung Pharmacokinetic Profile of Voriconazole Upon Pulmonary Delivery in Mice","volume":"13","author":"Paul","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2026.119691_bib147","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1021\/mp500808t","article-title":"Development of an Inhaled Controlled Release Voriconazole Dry Powder Formulation for the Treatment of Respiratory Fungal Infection","volume":"12","author":"Arora","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib148","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/acs.molpharmaceut.8b00907","article-title":"Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation","volume":"16","author":"Moon","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib149","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejpb.2008.12.014","article-title":"Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution","volume":"72","author":"Tolman","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119691_bib150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpharm.2009.06.003","article-title":"Dose tolerability of chronically inhaled voriconazole solution in rodents","volume":"379","author":"Tolman","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib151","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.01657-08","article-title":"Inhaled Voriconazole for Prevention of Invasive Pulmonary Aspergillosis","volume":"53","author":"Tolman","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2026.119691_bib152","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/acs.molpharmaceut.5b00064","article-title":"Pulmonary Delivery of Voriconazole Loaded Nanoparticles Providing a Prolonged Drug Level in Lungs: A Promise for Treating Fungal Infection","volume":"12","author":"Das","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib153","first-page":"921","article-title":"Foaming of nebulized albuterol","volume":"46","author":"Marino","year":"1989","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib154","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejps.2010.01.001","article-title":"vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution","volume":"39","author":"Yang","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119691_bib155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12951-020-00731-1","article-title":"Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention","volume":"19","author":"Kaur","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.biopha.2026.119691_bib156","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/17425247.2016.1114603","article-title":"Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability","volume":"13","author":"Arora","year":"2016","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.biopha.2026.119691_bib157","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/jof10030191","article-title":"A Phase I\/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis","volume":"10","author":"Fort\u00fan","year":"2024","journal-title":"J. Fungi"},{"key":"10.1016\/j.biopha.2026.119691_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102233","article-title":"Safety and usefulness of nebulized liposomal amphotericin B: Systematic scoping review","volume":"82","author":"Hagiya","year":"2023","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119691_bib159","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/pharmaceutics14030641","article-title":"Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections","volume":"14","author":"Brunet","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119691_bib160","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.nano.2015.02.012","article-title":"Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis","volume":"11","author":"Shirkhani","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2026.119691_bib161","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijpharm.2012.07.028","article-title":"Amphotericin B lipid nanoemulsion aerosols for targeting peripheral respiratory airways via nebulization","volume":"436","author":"Nasr","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib162","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2012.07.012","article-title":"Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity","volume":"436","author":"Fauvel","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(00)00522-6","article-title":"Ligand directed macrophage targeting of amphotericin B loaded liposomes","volume":"210","author":"Vyas","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib164","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jps.22274","article-title":"Development of Respirable Nanomicelle Carriers for Delivery of Amphotericin B by Jet Nebulization","volume":"100","author":"Gilani","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119691_bib165","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijpharm.2014.05.066","article-title":"Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation","volume":"471","author":"Gangadhar","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib166","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jconrel.2012.04.004","article-title":"The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection","volume":"160","author":"Alsaadi","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119691_bib167","first-page":"45","article-title":"Preparation, statistical optimization and in-vitro characterization of a dry powder inhaler (DPI) containing solid lipid nanoparticles encapsulating amphotericin B: ion paired complexes with distearoyl phosphatidylglycerol","volume":"19","author":"Yeganeh","year":"2020","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.biopha.2026.119691_bib168","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17425247.4.6.607","article-title":"The nanoscale in pulmonary delivery. Part 2: formulation platforms","volume":"4","author":"Rogueda","year":"2007","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.biopha.2026.119691_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119671","article-title":"Inhaled nanoparticles\u2013An updated review","volume":"587","author":"Praphawatvet","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119691_bib170","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/17425255.2014.916276","article-title":"Toxicological perspectives of inhaled therapeutics and nanoparticles","volume":"10","author":"Hayes","year":"2014","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.biopha.2026.119691_bib171","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/oem.2005.024802","article-title":"The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area","volume":"64","author":"Monteiller","year":"2007","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.biopha.2026.119691_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103461","article-title":"Steps toward nebulization in-use studies to understand the stability of new biological entities","volume":"28","author":"Montefusco-Pereira","year":"2023","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.biopha.2026.119691_bib173","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4187\/respcare.05500367","article-title":"The inhalation of drugs: Advantages and problems","volume":"50","author":"Rau","year":"2005","journal-title":"Respir. Care"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:31:28Z","timestamp":1785886288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":173,"alternative-id":["S0753332226007274"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119691","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation drug delivery systems for aspergillosis: Overcoming barriers in antifungal therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119691"}}